Tresiba® demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
New Orleans, US, 11 June 2016 – New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection U-100) resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin glargine U-100. 1,2 Results from the SWITCH 1 and 2 trials, the first […]